瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者的临床疗效与安全性评价

Clinical Efficacy and Safety of Rosuvastatin and Atorvastatin in Patients with Acute Myocardial Infarction

目的探讨瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者的临床疗效与安全性。方法选取我院(2015年1月至2017年1月)收治的90例急性心肌梗死患者为研究对象,将本组患者根据不同治疗药物分为两组,观察组45例患者给予瑞舒伐他汀治疗,对照组45例患者给予阿托伐他汀治疗,对比两组患者生化指标和治疗依从性、耐受性以及安全性。结果治疗前两组患者HDL-C、TG、LDL-C、TC、TNF-α、IL-8、hs-CRP水平对比差异不明显,无统计学意义(P>0.05);治疗后观察组患者LDL-C、TC、TNF-α、IL-8、hs-CRP水平明显低于对照组,差异具有统计学意义(P<0.05)。观察组有2例患者因肌痛、肝功能异常等药物耐受性原因,停止调脂治疗,对照组有3例,两组患者药物耐受性对比95.56%/93.33%差异不明显,无统计学意义(P>0.05);治疗6个月后,观察组失访4例,对照组失访11例,观察组患者治疗依从性91.11%明显高于对照组75.56%,差异具有统计学意义(P<0.05)。术后6个月,观察组未发生不良心血管事件,对照组有8例不稳定心绞痛,均没有出现心力衰竭和猝死,观察组患者不良心血管事件发生率0.00%明显低于对照组17.78%,差异具有统计学意义(P<0.05);冠状动脉电子计算机断层扫描显示,观察组患者支架远端血管显影良好率和支架内再狭窄发生率95.56%、4.44%明显低于对照组84.44%、13.33%,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀较阿托伐他汀改善急性心肌梗死患者LDL-C、TC、TNF-α、IL-8、hs-CRP水平更为明显,且瑞舒伐他汀还能明显降低心绞痛等不良心血管事件发生率和支架内再狭窄发生率,治疗依从性好。

Objective To explore the clinical efficacy and safety of rosuvastatin and atorvastatin in patients with acute myocardial infarction.Methods 90 patients with acute myocardial infarction treated in our hospital(January 2015-January 2017)were selected as the research object.The patients were divided into two groups according to different treatment drugs,45 patients in the observation group were treated with rosuvastatin,and 45 patients in the control group were treated with atorvastatin,and the biochemical indexes and treatment of the two groups were compared.Compliance,tolerance and safety.Results The differences of HDL-C,TG,LDL-C,TC,TNF-alpha,IL-8 and hs-CRP in the two groups were not significant(P>0.05),and the levels of LDL-C,TC,TNF-alpha,IL-8,etc.in the observation group were significantly lower than those in the control group,and the difference was statistically significant.There were 2 patients in the observation group,which had 2 patients due to myalgia and abnormal liver function,and stopped fat regulation.There were 3 cases in the control group.The difference between the two groups was not significant and no significant difference(P>0.05).After 6 months of treatment,4 cases were lost in the observation group and 11 cases in the control group were lost.The treatment group was treated with treatment.Compliance 91.11%was significantly higher than that of the control group(75.56%),and the difference was statistically significant(P<0.05).6 months after the operation,there were no adverse cardiovascular events in the observation group.There were 8 unstable angina pectoris in the control group,no heart failure and sudden death.The incidence of adverse cardiovascular events in the observation group was 0%lower than that of the control group(17.78%).The difference was statistically significant(P<0.05);coronary artery electronic computed tomography scan showed that In the observation group,the good rate of distal vascular development and the incidence of restenosis in the stent were 95.56%and 4.44%,which were significantly lower than those of the control group(84.44%and 13.33%),and the difference was statistically significant(P<0.05).Conclusion Rosuvastatin is more obvious than atorvastatin on the improvement of LDL-C,TC,TNF-alpha,IL-8 and hs-CRP in patients with acute myocardial infarction,and rosuvastatin can significantly reduce the incidence of adverse cardiovascular events and the incidence of restenosis in the stent,and the compliance of the treatment is good.